Novel TKIs and ADC-based therapies offer higher response rates and improved survival in HER2 altered NSCLC; these therapeutic breakthroughs and increasing understanding of HER2 pathways bring hope for this challenging disease. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.